List of antiretroviral fixed-dose combinations

Antiretroviral drugs are used to manage HIV/AIDS. Multiple antiretroviral drugs are often combined into a single pill in order to reduce pill burden.

Some of these combinations are complete single-tablet regimens; the others must be combined with additional pills to make a treatment regimen.

Brand name(s)	Ingredients (INN)					Food and Drug Administration (FDA) approval date	European Medicines Agency (EMA) approval date	Health Canada approval date	Company	Single-tablet regimen?
Brand name(s)	NRTIs / NtRTIs	NNRTI	INSTI	PI	PK enhancer	Food and Drug Administration (FDA) approval date	European Medicines Agency (EMA) approval date	Health Canada approval date	Company	Single-tablet regimen?
Combivir	lamivudine zidovudine					September 26, 1997			ViiV Healthcare	No
Kaletra (developed countries) Aluvia (developing countries)				lopinavir	ritonavir	September 15, 2000			Abbott Laboratories	No
Trizivir	abacavir lamivudine zidovudine					November 15, 2000			ViiV Healthcare	Yes
Epzicom (US) Kivexa (EU, RU)	abacavir lamivudine					August 2, 2004			ViiV Healthcare	No
Generics, e.g., Triomune	lamivudine stavudine	nevirapine				(not approved)			(many companies)	Yes
Generics, e.g., Duovir-N	lamivudine zidovudine	nevirapine				(not approved)			(many companies)	Yes
Truvada	emtricitabine tenofovir disoproxil					August 2, 2004			Gilead Sciences	No
Atripla	emtricitabine tenofovir disoproxil	efavirenz				July 12, 2006			Gilead Sciences Bristol-Myers Squibb	Yes
Complera (US) Eviplera (EU, RU)	emtricitabine tenofovir disoproxil	rilpivirine				August 10, 2011			Gilead Sciences Janssen Pharmaceutica	Yes
Stribild	emtricitabine tenofovir disoproxil		elvitegravir		cobicistat	August 27, 2012			Gilead Sciences	Yes
Triumeq	abacavir lamivudine		dolutegravir			August 22, 2014			ViiV Healthcare	Yes
Evotaz				atazanavir	cobicistat	January 29, 2015			Bristol-Myers Squibb	No
Prezcobix (US) Rezolsta (EU)				darunavir	cobicistat	January 29, 2015			Janssen Pharmaceutica	No
Dutrebis	lamivudine		raltegravir			February 6, 2015			Merck & Co.	No
Genvoya	emtricitabine tenofovir alafenamide		elvitegravir		cobicistat	November 5, 2015			Gilead Sciences	Yes
Odefsey	emtricitabine tenofovir alafenamide	rilpivirine				March 1, 2016			Gilead Sciences	Yes
Descovy	emtricitabine tenofovir alafenamide					April 4, 2016			Gilead Sciences	No
Juluca		rilpivirine	dolutegravir			November 21, 2017			ViiV Healthcare	Yes
Symfi, Symfi Lo	lamivudine tenofovir disoproxil	efavirenz				February 5, 2018 (Symfi Lo) March 22, 2018 (Symfi)			Mylan	Yes
Biktarvy	emtricitabine tenofovir alafenamide		bictegravir			February 7, 2018			Gilead Sciences	Yes
Cimduo, Temixys	lamivudine tenofovir disoproxil					February 28, 2018			Mylan	No
Symtuza	emtricitabine tenofovir alafenamide			darunavir	cobicistat	July 17, 2018			Janssen Pharmaceutica	Yes
Delstrigo	lamivudine tenofovir disoproxil	doravirine				August 30, 2018			Merck & Co.	Yes
Dovato	lamivudine		dolutegravir			April 8, 2019			ViiV Healthcare	Yes
Cabenuva		rilpivirine	cabotegravir			January 21, 2021		March 18, 2020^[1]^[2]	ViiV Healthcare	No

References

^ "Cabenuva Product information". Health Canada. 25 April 2012. Retrieved 22 January 2021.
^ "ViiV Healthcare announces first global regulatory approval of Cabenuva; the first complete, long-acting, regimen for the treatment of HIV". GSK. Retrieved 23 January 2021.

External links

"Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets". ClinicalInfo. This article incorporates text from this source, which is in the public domain.

Antiviral drugs: antiretroviral drugs used against HIV (primarily J05)

Capsid inhibitors

Lenacapavir (LEN)

Entry/fusion inhibitors
(Discovery and development)

gp41 (Enfuvirtide (ENF, T-20))^◊
CCR5 (Maraviroc (MVC)
Vicriviroc^†, Cenicriviroc^†, Leronlimab^†)
CD4 (Ibalizumab (IBA), Semzuvolimab^§)
gp120 (Fostemsavir (FTR))

Integrase inhibitors
(Integrase strand transfer inhibitors (INSTI))

Maturation inhibitors

Protease Inhibitors (PI)
(Discovery and development)

1^st generation	Amprenavir (APV)^‡ Fosamprenavir (FPV) Indinavir (IDV)^◊ Lopinavir (LPV) Nelfinavir (NFV)^◊ Ritonavir (RTV)^# Saquinavir (SQV)^◊
2^nd generation	Atazanavir (ATV)°^# Darunavir (DRV)°^# Tipranavir (TPV)^◊ TMC-310911^§

Reverse-transcriptase
inhibitors (RTIs)

Nucleoside and
nucleotide (NRTI)

Nucleoside analogues/NRTIs: Abacavir (ABC)^#
Didanosine (ddI)^◊
Emtricitabine (FTC)
Lamivudine (3TC)^#
Stavudine (d4T)^◊
Zalcitabine (ddC)^‡
Zidovudine (AZT, ZDV)^#
Amdoxovir^†
Apricitabine^†
Censavudine^†
Elvucitabine^†
Islatravir (EFdA, ISL)^§
Racivir^†
Stampidine^†

Non-nucleoside (NNRTI)
(Discovery and development)

1^st generation	Efavirenz (EFV)^# Nevirapine (NVP)^# Delavirdine (DLV)^‡
2^nd generation	diarylpyrimidines Dapivirine (DPV) Etravirine (ETR) Rilpivirine (RPV) Doravirine (DOR) Elsulfavirine (ESV)

Combined formulations

Pharmacokinetic boosters

Experimental agents

Uncoating inhibitors	TRIM5alpha (gene)
Transcription inhibitors	Tat antagonists
Translation inhibitors	Trichosanthin
BNAbs	Elipovimab
Other	Abzyme BIT225^† Calanolide A Ceragenin Cyanovirin-N Diarylpyrimidines Epigallocatechin gallate (EGCG) Foscarnet Fosdevirine^† Griffithsin Hydroxycarbamide KP-1461^† Miltefosine Portmanteau inhibitors Scytovirin Seliciclib^† Synergistic enhancers Tre recombinase Zinc finger protein transcription factor
Failed agents	Aplaviroc Atevirdine Brecanavir Capravirine Dexelvucitabine Droxinavir Lasinavir Emivirine Lersivirine Lodenosine Loviride Mozenavir Palinavir Telinavir

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

°DHHS recommended initial regimen options. ^◊Formerly or rarely used agent.

RNA virus antivirals (primarily J05, also S01AD and D06BB)

Hepatitis C

NS3/4A protease inhibitors (–previr)	Asunaprevir Boceprevir^‡ Ciluprevir^§ Danoprevir^† Faldaprevir^‡ Glecaprevir Grazoprevir Narlaprevir Paritaprevir Simeprevir Sovaprevir^† Telaprevir^‡ Vaniprevir Vedroprevir^§ Voxilaprevir
NS5A inhibitors (–asvir)	Daclatasvir^# Elbasvir Ledipasvir Odalasvir^† Ombitasvir Pibrentasvir Ravidasvir^† Ruzasvir^† Samatasvir^† Velpatasvir
NS5B RNA polymerase inhibitors (–buvir)	Beclabuvir^† Bemnifosbuvir^† Dasabuvir^# Deleobuvir^§ Filibuvir^§ GS-6620^§ IDX-184^§ Setrobuvir^§ Sofosbuvir^# Tegobuvir^§ TMC-647055^§ Radalbuvir^† Uprifosbuvir^†
Combination drugs	Elbasvir/grazoprevir Glecaprevir/pibrentasvir Ledipasvir/sofosbuvir^# Ombitasvir/paritaprevir/ritonavir^# Sofosbuvir/daclatasvir Sofosbuvir/velpatasvir^# Sofosbuvir/velpatasvir/voxilaprevir

Hepatitis D

Bulevirtide

Picornavirus

viral entry: Pleconaril^†

Anti-influenza agents

neuraminidase inhibitors/release phase (Oseltamivir^#
Zanamivir
Peramivir, Laninamivir^†)

Multiple/general

Interferon	Interferon alfa 2b Peginterferon alfa-2a^# Peginterferon alfa-2b^#
3CL protease inhibitors (–trelvir)	Ensitrelvir^† Lufotrelvir Nirmatrelvir^† (+ritonavir)^† Rupintrivir Simnotrelvir (+ritonavir^†)
RNA pol inhibitors	CMX521^§ Deuremidevir^† Favipiravir Galidesivir^† GS-441524^§ Remdesivir MK-608^§ Mericitabine^† Molnupiravir NITD008^§ Ribavirin^# Taribavirin^† Triazavirin Valopicitabine^†
Multiple/Unknown/Other	EICAR^§ Merimepodib^§ Moroxydine Presatovir^†

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This page was last edited on 9 February 2024, at 16:33

From Wikipedia, the free encyclopedia

References

External links